

## A reaction-diffusion model of spatial propagation of $A\beta$ oligomers in early stage Alzheimer's disease

Martin Andrade-Restrepo, Ionel Sorin Ciuperca, Paul Lemarre, Laurent

Pujo-Menjouet, Leon Tine

### ▶ To cite this version:

Martin Andrade-Restrepo, Ionel Sorin Ciuperca, Paul Lemarre, Laurent Pujo-Menjouet, Leon Tine. A reaction-diffusion model of spatial propagation of A $\beta$  oligomers in early stage Alzheimer's disease. Journal of Mathematical Biology, 2021, 82 (5), pp.1-25. 10.1007/s00285-021-01593-3 . hal-03533359

## HAL Id: hal-03533359 https://hal.science/hal-03533359

Submitted on 18 Jan2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# A reaction-diffusion model of spatial propagation of $A\beta$ oligomers in early stage Alzheimer's disease

Martin Andrade-Restrepo · Ionel Sorin Ciuperca · Paul Lemarre · Laurent Pujo-Menjouet · Léon Matar Tine

Received: date / Accepted: date

Abstract The misconformation and aggregation of the protein Amyloid-Beta  $(A\beta)$  is a key event in the propagation of Alzheimer's Disease (AD). Different types of assemblies are identified, with long fibrils and plaques deposing during the late stages of AD. In the earlier stages, the disease spread is driven by the formation and the spatial propagation of small amorphous assemblies called oligomers. We propose a model dedicated to studying those early stages, in the vicinity of a few neurons and after a polymer seed has been formed. We build a reaction-diffusion model, with a Becker-Döring-like system that includes fragmentation and size-dependent diffusion. We hereby establish the

P. Lemarre

Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5208, Inria, Institut Camille Jordan, F-69622 Villeurbanne, France E-mail: lemarre@math.univ-lyon1.fr

L. P. Menjouet

Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5208, Inria, Institut Camille Jordan, F-69622 Villeurbanne, France E-mail: pujo@math.univ-lyon1.fr

L. M. Tine

M. Andrade-Restrepo

Department of Applied Mathematics and Computer Science, Universidad del Rosario, Bogotá 111711, Colombia Institut Jacques Monod, CNRS UMR 7592, Université Paris Diderot, Université de Paris, F-750205, Paris, France E-mail: martin.andrade@urosario.edu.co I. S. Ciuperca Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5208, Institut Camille Jordan,

Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5208, Institut Camille Jordan, F-69622 Villeurbanne, France E-mail: ionel.ciuperca@univ-lyon1.fr

Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5208, Inria, Institut Camille Jordan, F-69622 Villeurbanne, France E-mail: matar.tine@univ-lyon1.fr

theoretical framework necessary for the proper use of this model, by proving the existence of solutions using a fixed point method.

**Keywords** Alzheimer's Disease  $\cdot$  Reaction-diffusion  $\cdot$  Partial differential equations

Mathematics Subject Classification (2010) 35K57 · 92B05

#### **1** Introduction

Alzheimer's disease (AD) is the most common of neurodegenerative diseases, a group that also includes Parkinson's disease, Huntington disease, Creutzfeldt-Jakob disease, and transmissible spongiform encephalopathies. AD consists in a gradual neuron loss not consistent with habitual aging. As is the case for these other diseases, AD is associated with the misconformation, aggregation and propagation of different proteins in the neural system (Soto, 2003), in particular Amyloid-beta ( $A\beta$ ) and Tau (Hardy and Higgins, 1992; Hardy, 2003). These proteins can adopt different stable conformations. Some of them, called misconformations, lead to the creation of structured assemblies that are reliable biological markers of the disease (Haass and Selkoe, 2007; Ittner and Götz, 2011; Jack Jr et al., 2013).

 $A\beta$  is formed by cleavage of the Amyloid Precursor Protein (APP), which is produced by healthy neurons and attaches to the membrane of neuron cells with an endogenous purpose that remains unclear (Hiltunen et al., 2009). The self-assembly of  $A\beta$  leads to different types of structures. Fibrils are long linear polymers, that can coalesce into large tangles called plaques. Plaques constitute the visible deposits observed in most late-stage AD patients. During the earlier stages smaller and less ordered structures are also formed, commonly named oligomers. To the best of our knowledge the interactions between the different types of structures are unclear, but it has been shown that oligomers appear early on during the onset of Alzheimer's disease (Oda et al., 1994, 1995), while fibrils and plaques become detectable much later. Oligomers are soluble and difficult to detect, but their role in AD propagation and pathology is believed to be essential (Čižas et al., 2011; Haass and Selkoe, 2007; Sengupta et al., 2016; Zhao et al., 2012).

The generally accepted mechanism for the onset of AD is the so-called *cascade hypothesis* (Yankner, 1996; Hardy and Higgins, 1992; Haass and Selkoe, 2007; Cohen et al., 2013). The first appearance of misfolded  $A\beta$  in the form of oligomers is a rare and highly stochastic event, possibly favored by mutations or co-factors. Monomers can spontaneously change conformation and assemble into small proto-oligomers. This process is termed (primary) nucleation. Once the process has started and a seed has appeared, the oligomers replicate and propagate rapidly (Morales et al., 2012; Olsson et al., 2018; Sowade and Jahn, 2017). This second step is usually referred to as secondary nucleation (Cohen et al., 2013). Although the precise phenomenon that allows oligomers to replicate is not known, it can be described as a prion-like propagation (Rasmussen et al., 2017). Moreover, recent discoveries show the existence of a positive feedback where infected cells increase production of  $A\beta$  proteins leading to a further acceleration of the pathology (Elliott et al., 2018). The propagation of misconformed proteins in the brain is the result of multiple phenomena acting at different scales. At smaller scales diffusion drives the propagation, but for long range propagation other mechanisms come into play (e.g. exosomes)(Xiao et al., 2017). As the pathology progresses, stagnant fibrillar structures and plaques begin to form. These structures remain fixed or travel slowly. However, breakage of fibrils potentially produces new seeds that propagate fast and drive the spatial progression and the development of AD (Cohen et al., 2013). It is only at advanced stages of the disease and at longer-time-scales that the symptoms of dementia appear (Perrin et al., 2009). The spatial and temporal progression of biomarkers and the appearance of symptoms in AD is thus highly complex and heterogeneous (Storandt et al., 2002; Ohm et al., 1995; Smith, 2002; Perrin et al., 2009). For this reason, it is of particular interest for the biomedical community to understand the mechanisms of propagation and replication of  $A\beta$  oligomers, especially during the early latent stages of AD. Insights into this phenomenon could help develop therapeutic strategies before the first signs of dementia (Eleuteri et al., 2015; Haass and Selkoe, 2007). Having a mechanistic model of the oligomers replication coupled with spatial propagation is a first step towards identifying the key parameters in the early stage development of the disease. If this mechanistic model is validated (which is the following step in the process), hopefully some therapeutic strategies could be proposed by focusing on the events that impact propagation the most.

One approach towards this purpose is via mathematical and computational modeling. The dynamics of misfolded proteins and their role in neurodegenerative disorders have attracted considerable attention from mathematicians (Carbonell et al., 2018) with a strong increase during the last 30 years. Most influential studies have used systems of Ordinary Differential Equations (ODEs) to model and replicate the dynamics of aggregation and proliferation of prion proteins (Eigen, 1996; Harper and Lansbury Jr, 1997; Nowak et al., 1998; Greer et al., 2006). Different spatial extensions to these models have been proposed under the assumption of isotropic diffusion (Matthäus, 2006), diffusion combined with a network topology (Matthaeus, 2009; Raj et al., 2012) or lattice-like domains based on cell connectivity networks (Stumpf and Krakauer, 2000). Concerning AD, mathematical modeling has focused on analyzing microscopic processes related to prion-like replication or joint prion-A $\beta$ dynamics. Recently, a number of multi-scale, non-spatial models have been aimed at studying the evolution of monomers, oligomers, fibrils, and plaques (Ciuperca et al., 2018; Helal et al., 2014, 2018). Some descriptions use discrete aggregate sizes, others favor continuous sizes. The two approaches are similar at large aggregate sizes but have discrepancies at the scale of small oligomers (Doumic et al., 2009; Vasseur et al., 2002; Velázquez, 1998). In the case of discrete sizes, models generally use the Becker-Döring Equations. Spatial extensions of these models have been rare with the possible exception of (Bertsch et al., 2016, 2017) where interesting results where achieved but where potentially essential biological factors were not considered when extrapolating microscopic processes to larger-spatial scales. Integration of microscopic, mesoscopic and macroscopic scales is difficult as there are different processes intervening at each level (e.g spreading through exosomes, axons, or cerebrospinal fluid). Overall, few models have successfully integrated molecular and large scales (Carbonell et al., 2018).

In the present study we introduce a model based on a discrete growthfragmentation system of oligomeric species, in which we include spatial diffusion. We focus our analysis on the early stages of the pathology, after a seed has appeared and oligomers start replicating. The resulting system of partial differential equations aims at representing the simultaneous replication and spatial diffusion of  $A\beta$  oligomers in the vicinity of a few neurons. More precisely, the considered  $A\beta$  monomers can assemble first into proto-oligomers and then oligomers. Proto-oligomers are small unstable polymers that grow by addition of monomers (**polymerization**) and shrink by loosing monomers (depolymerization). Proto-oligomers can also fragment (fragmentation) into smaller pieces. Those processes are illustrated in Figure 1. The goal here is to establish a robust mathematical framework for the study of this model with theoretical results ensuring the relevance and stability of the model. This model is novel in the sense that it couples the chemical replication oligomers with their spatial-dependent toxicity. The results that we obtain here differ from the classical models of growth-fragmentation with spatial diffusion in that the oligomers have a direct impact on the production of monomers. This interplay needs to be dealt with and the mathematical study needs to be adapted. In the preliminary work (Andrade-Restrepo et al., 2020), we carried out a modeling work based on the description and the numerical simulation of this model where a simple representation of the oligomers neurotoxic effect is included. The numerical results reveal that the oligomers spatial dynamics are very sensitive to the balance between their diffusion and their replication. The paper is organized as follows. In Section 2 we describe the considered problem, Section 3 is devoted to setting up an associated regularized problem and the proof of its well-posedness. In Section 4 we prove the existence of solutions to our initial problem.

#### 2 Initial problem description

#### 2.1 Domain description and variables definition

Let us describe the problem at hand and its mathematical formulation. We consider a bounded domain  $\Omega \subset \mathbb{R}^n$ , with n = 2 or n = 3. A number N of holes in the domain, representing the neuron cells, are defined by the boundaries  $\partial \omega_k$  for  $k = 1 \in \{1, \ldots, N\}$ . The exterior boundary of  $\Omega$  is denoted  $\Gamma$ . The whole



Fig. 1 Illustration of the biological species and interactions represented in the model

boundary of  $\varOmega$  is thus

$$\partial \Omega = \Gamma \cup \bigcup_{k=1}^N \partial \omega_k.$$

This geometric description of the domain is illustrated in Figure 2.



Fig. 2 Illustration of the mathematical domain used in the model

We consider a time interval [0, T] with T > 0. The unknowns of the problem are  $m, \mu_2, \mu_3, \dots, \mu_{i_0} : \Omega \times (0, T) \mapsto \mathbb{R}$  with  $i_0 \in \mathbb{N}, i_0 \geq 5$ . Here m := m(x, t)represents the monomers concentration,  $\mu_i := \mu_i(x, t)$  with  $i \in \{2, \dots, i_0 - 1\}$ represents the concentration of proto-oligomers of size i and  $\mu_{i_0} := \mu_{i_0}(x, t)$  is the concentration of oligomers.

We look for solutions that are  $L^2$  both in time and in space for generality, and that are non-negative. For this purpose, let us define the Banach space

$$X = L^2(0, T : L^2(\Omega))$$

which is identified with  $L^2(\Omega \times (0,T))$ .

In the following for any space  $\mathcal{B}$  of functions defined on  $(0,T) \times \Omega$  or on  $\Omega$  only, we denote by  $\mathcal{B}_+$  the subset of non negative function of  $\mathcal{B}$ .

Our problem will be defined on  $\underbrace{X_+ \times X_+ \cdots \times X_+}_{i_0 \text{ times}}$  which is denoted by  $X_+^{i_0}$ .

#### 2.2 Parameters description and assumptions

All parameters introduced in the following are assumed to be real and nonnegative. Each species, from monomers to oligomers of size  $i_0$ , has its own diffusion coefficient denoted as  $D_i$  for size i. Monomers are degraded from the system with rate  $\delta$ . Proto-oligomers grow by monomer addition with polymerization rate  $r_i$  for size i, and they can lose one monomer by depolymerization with rate b (constant). Proto-oligomers can also fragment with a homogeneous fragmentation kernel and a fragmentation rate  $\beta \times (i-1)$  for size i. Finally  $\gamma$  denotes the rate of absorption of matter at the external boundaries of the domain, and  $B_k$  denotes the time-dependent rate of monomer production by neuron k. A summary of all parameters and variables is proposed in Table 1, and the biological model behind those processes is illustrated in Figure 1.

In order to simplify the equations formulation, we define the following coefficients

$$a_{2,2} = \beta, a_{2,3} = 2\beta + b,$$
  
for  $j = 4, \dots, i_0 - 1, a_{2,j} = 2\beta,$   
for  $i = 3, \dots, i_0 - 2, a_{i,i} = b + \beta(i - 1), a_{i,i+1} = 2\beta + b,$   
and for  $j = i + 2, i_0 - 1, a_{i,j} = 2\beta,$   
 $a_{i_0 - 1, i_0 - 1} = b + \beta(i_0 - 2).$ 

The monomer production rate  $B_k$  of neuron k, for  $k \in \{1, ..., N\}$ , satisfies the equations

$$B'_{k}(t) = -\tau \left( \int_{\mathbb{R}^{N} - \omega_{k}} \mu_{i_{0}}(x, t) \eta_{k}(x) dx \right) B_{k},$$
  

$$B_{k}(0) = B^{0}_{k}.$$
(1)

The function  $\eta_k$  is the indicator function of the oligomer action zone around neuron k, taking its values in  $\{0, 1\}$ . The oligomer action zone is a bounded domain containing the neuron  $\omega_k$ , in which the oligomers of concentration  $\mu_{i_0}$  have an impact on the monomer production rate, as described by (1). In practice for numerical simulations (already done in (Andrade-Restrepo et al., 2020)), the neurons are defined as circles and the oligomer action zones as larger concentric circles around the neurons, as it is illustrated in Figure 2.

*Remark 1* We observe that  $B_k$  is expressed in terms of  $\mu_{i_0}$  by

$$B_k(t) = B_k^0 \exp\left(-\tau \int_0^t \int_{\mathbb{R}^n - \omega_k} \mu_{i_0}(x, s)\eta_k(x)dxds\right).$$
 (2)

One additional assumption is that the polymerization rate is an increasing function of the proto-oligomers size

for 
$$i = 2, \dots, i_0 - 2, r_i \le r_{i+1}$$
. (3)

With all the parameters introduced and the assumptions established, we can formulate the problem at hand.

#### 2.3 Problem formulation

The problem is defined as follows

**Problem 1** ( $\mathcal{P}$ ) Find  $(m, \mu_2, \mu_3 \dots, \mu_{i_0}) \in X^{i_0}_+$  such that

$$\frac{\partial m}{\partial t} = D_1 \Delta m - m \left( \sum_{j=2}^{i_0-1} r_j \mu_j + \delta \right) + \sum_{j=3}^{i_0-1} b \mu_j + 2\beta \sum_{j=2}^{i_0-1} \mu_j, \quad (4)$$

$$\frac{\partial \mu_2}{\partial t} = D_2 \Delta \mu_2 - m r_2 \mu_2 - a_{2,2} \mu_2 + \sum_{j=3}^{i_0-1} a_{2,j} \mu_j, \tag{5}$$

for  $i = 3, \ldots, i_0 - 2$ ,

$$\frac{\partial \mu_i}{\partial t} = D_i \Delta \mu_i + m r_{i-1} \mu_{i-1} - m r_i \mu_i - a_{i,i} \mu_i + \sum_{j=i+1}^{i_0-1} a_{i,j} \mu_j, \quad (6)$$

$$\frac{\partial \mu_{i_0-1}}{\partial t} = D_{i_0-1} \Delta \mu_{i_0-1} + m r_{i_0-2} \mu_{i_0-2} - m r_{i_0-1} \mu_{i_0-1} - a_{i_0-1,i_0-1} \mu_{i_0-1},$$
(7)

$$\frac{\partial \mu_{i_0}}{\partial t} = D_{i_0} \Delta \mu_{i_0} + m r_{i_0 - 1} \mu_{i_0 - 1}.$$
(8)

We add the boundary conditions

$$D_1 \frac{\partial m}{\partial \nu} = -\gamma m \text{ on } \Gamma, \tag{9}$$

for 
$$k = 1, ..., N$$
,  $D_1 \frac{\partial m}{\partial \nu} = B_k(t)$  on  $\partial \omega_k$ , (10)

and for 
$$i = 2, ..., i_0, \ D_i \frac{\partial \mu_i}{\partial \nu} = -\gamma \mu_i \text{ on } \Gamma,$$
 (11)

$$D_i \frac{\partial \mu_i}{\partial \nu} = 0 \text{ on } \partial \omega_k.$$
(12)

Finally we have the initial conditions

for almost all 
$$x \in \Omega$$
, and for  $i = 1, \dots, i_0, \mu_i(t = 0, x) = \mu_i^0(x)$ ,  
for almost all  $x \in \Omega, m(t = 0, x) = m^0(x)$ , (13)

with each initial concentration distribution  $m^0, \mu_2^0, \mu_3^0, \ldots, \mu_{i_0}^0$  taken in  $L^2(\Omega)$  and non-negative.

We recall that this model is introduced in more detail and with biological interpretation of every term in (Andrade-Restrepo et al., 2020). More precisely, numerical simulations are performed and strong dependency of Alzheimer's disease progression and balance between oligomers diffusion and replication is highlighted.

Our purpose is here to establish the theoretical well-posedness of the model by proving the existence of solutions. In this prospect, we use a regularization method.

Symbol	Description
$m$ (or $\mu_1$ )	Local density of $A\beta$ monomers
$\mu_i, i = 2 \dots i_0 - 1$	Local density of proto-oligomers
$\mu_{i_0}$	Local density of oligomers
$D_i$	Diffusion coefficient of size $i$ particles
δ	Degradation coefficient of monomers
$\gamma$	Boundary absorption rate
$r_i$	Polymerization rate of size $i$ proto-oligomers
b	Depolymerization rate
β	Fragmentation rate
$B_k$	Monomer production rate on the membrane of neuron $k$

 Table 1 Model variables and parameters

#### **3** The associated regularized problem

We first define a regularized problem associated with  $(\mathcal{P})$ , by introducing a regularization of the monomer concentration.

#### 3.1 Setting up a regularization

We denote by  $\mathcal{D}(\mathbb{R}^{n+1})$  the set of test functions on  $\mathbb{R}^{n+1}$ , *i.e.* the set of infinitely smooth and compactly supported functions from  $\mathbb{R}^{n+1}$  to  $\mathbb{R}$ . Let us consider, for  $\varepsilon > 0$ , a mollifier function  $\theta_{\varepsilon} : \begin{cases} \mathbb{R}^{n+1} \to \mathbb{R} \\ (x,t) \to \theta_{\varepsilon}(x,t) \end{cases}$ , with the following properties

$$\theta_{\varepsilon} \in \mathcal{D}(\mathbb{R}^{n+1}), supp(\theta_{\varepsilon}) \subset B_{\mathbb{R}^{n+1}}(0,\varepsilon), \theta_{\varepsilon} \ge 0, \int_{\mathbb{R}^{n+1}} \theta_{\varepsilon}(x,t) dx dt = 1,$$

where  $B_{\mathbb{R}^{n+1}}(0,\varepsilon)$  is the ball centered in 0 and of radius  $\varepsilon$  in  $\mathbb{R}^{n+1}$ . For any function  $v \in L^1(\Omega \times (0,T))$  we denote by  $v * \theta_{\varepsilon}$  the convolution defined on  $\mathbb{R}^{n+1}$  by

$$(v*\theta_{\varepsilon})(x,t) = \int_{\mathbb{R}^{n+1}} v(x-y,t-s)\theta_{\varepsilon}(y,s)dyds$$

where v is extended by 0 outside  $\Omega \times (0,T)$ . The properties of  $\theta_{\varepsilon}$  give the regularity of  $(v * \theta_{\varepsilon})$ , more precisely

$$v * \theta_{\varepsilon} \in C^{\infty}(\Omega \times [0, T]).$$

The first step to study the existence of solutions to the initial problem  $\mathcal{P}$  is to prove the existence of solutions to the regularized problem  $(\mathcal{P}_{\varepsilon})$  defined below for any  $\varepsilon > 0$ , using a fixed point argument. After this regularization step, we study the limit  $\varepsilon \to 0$  and obtain the existence of weak solutions to the problem  $(\mathcal{P})$ .

The problem  $(\mathcal{P}_{\varepsilon})$  is described as follows: find  $(m_{\varepsilon}, \mu_{2,\varepsilon}, \ldots, \mu_{i_0,\varepsilon})$  in  $X^{i_0}$  such that

$$\frac{\partial m_{\varepsilon}}{\partial t} = D_1 \Delta m_{\varepsilon} - m_{\varepsilon} \left( \sum_{j=2}^{i_0-1} r_j \mu_{j,\varepsilon} + \delta \right) + \sum_{j=3}^{i_0-1} b \mu_{j,\varepsilon} + 2\beta \sum_{j=2}^{i_0-1} \mu_{j,\varepsilon}, \quad (14)$$

$$\frac{\partial \mu_{2,\varepsilon}}{\partial t} = D_2 \Delta \mu_{2,\varepsilon} - (m_{\varepsilon} * \theta_{\varepsilon}) r_2 \mu_{2,\varepsilon} - a_{2,2} \mu_{2,\varepsilon} + \sum_{j=3}^{i_0-1} a_{2,j} \mu_{j,\varepsilon},$$
(15)

for 
$$i = 3, ..., i_0 - 2$$
,  

$$\frac{\partial \mu_{i,\varepsilon}}{\partial t} = D_i \Delta \mu_{i,\varepsilon} + (m_{\varepsilon} * \theta_{\varepsilon}) r_{i-1} \mu_{i-1,\varepsilon} - (m_{\varepsilon} * \theta_{\varepsilon}) r_i \mu_{i,\varepsilon} - a_{i,i} \mu_{i,\varepsilon} + \sum_{j=i+1}^{i_0 - 1} a_{i,j} \mu_{j,\varepsilon},$$
(16)

$$\frac{\partial \mu_{i_0-1,\varepsilon}}{\partial t} = D_{i_0-1} \Delta \mu_{i_0-1,\varepsilon} + (m_{\varepsilon} * \theta_{\varepsilon}) r_{i_0-2} \mu_{i_0-2,\varepsilon} - (m_{\varepsilon} * \theta_{\varepsilon}) r_{i_0-1} \mu_{i_0-1,\varepsilon} - a_{i_0-1,i_0-1} \mu_{i_0-1,\varepsilon},$$
(17)

$$\frac{\partial \mu_{i_0,\varepsilon}}{\partial t} = D_{i_0} \Delta \mu_{i_0,\varepsilon} + m_{\varepsilon} r_{i_0-1} \mu_{i_0-1,\varepsilon}, \tag{18}$$

The boundary and initial conditions are the same as for the problem  $(\mathcal{P})$ .

Remark 2 We would normally denote by  $(m_{\varepsilon}, \mu_{2,\varepsilon}, \ldots, \mu_{i_0,\varepsilon})$  the solution of problem  $(\mathcal{P}_{\varepsilon})$ , but for simplicity we omit the subscript  $\varepsilon$  in the following.

We can now study the existence of solutions to the regularized problem, by using a fixed-point method.

3.2 Existence of solutions for the regularized problem

Now we define the following application  $F_0: \begin{cases} (L^{\infty}(0,T:L^2(\Omega)))_+ \to X^{i_0-2}\\ \tilde{m} \to (\mu_2,\ldots,\mu_{i_0-1}) \end{cases}$ , where  $\mu_2, \ldots, \mu_{i_0-1}$  are solutions of the system

$$\begin{aligned} \frac{\partial \mu_2}{\partial t} &= D_2 \Delta \mu_2 - \tilde{m} r_2 \mu_2 - a_{2,2} \mu_2 + \sum_{j=3}^{i_0 - 1} a_{2,j} \mu_j, \\ \text{for } i &= 3, \dots, i_0 - 2, \\ \frac{\partial \mu_i}{\partial t} &= D_i \Delta \mu_i + \tilde{m} r_{i-1} \mu_{i-1} - \tilde{m} r_i \mu_i - a_{i,i} \mu_i + \sum_{j=i+1}^{i_0 - 1} a_{i,j} \mu_j, \\ \frac{\partial \mu_{i_0 - 1}}{\partial t} &= D_{i_0 - 1} \Delta \mu_{i_0 - 1} + \tilde{m} r_{i_0 - 2} \mu_{i_0 - 2} - \tilde{m} r_{i_0 - 1} \mu_{i_0 - 1} - a_{i_0 - 1, i_0 - 1} \mu_{i_0 - 1} \end{aligned}$$

with boundary and initial conditions as for the problem  $(\mathcal{P})$ .

Then we introduce the function  $F_{\varepsilon}: \begin{cases} X_+ \to X^{i_0-2} \\ \tilde{m} \to F_{\varepsilon}(\tilde{m}) = F_0(\tilde{m} * \theta_{\varepsilon}), \text{ for any } \tilde{m} \in X_+. \end{cases}$ Since  $\tilde{m} * \theta_{\varepsilon}$  is in  $(L^{\infty}(0, T : L^2(\Omega)))_+$  for any  $\tilde{m} \in X_+$  it is clear that  $F_{\varepsilon}$  is well defined as long as  $F_0$  is.

Now we consider the application  $G_{\varepsilon} : \begin{cases} X_{+}^{2} \to X^{2} \\ (\tilde{m}, \tilde{\mu}_{i_{0}}) \to (m, \mu_{i_{0}}). \end{cases}$ In the definition of  $G_{\varepsilon}$ , m is a solution to the reduced problem

$$\frac{\partial m}{\partial t} = D_1 \Delta m - m \left( \sum_{j=2}^{i_0 - 1} r_j \tilde{\mu}_j + \delta \right) + \sum_{j=3}^{i_0 - 1} b \tilde{\mu}_j + 2\beta \sum_{j=2}^{i_0 - 1} \tilde{\mu}_j,$$
$$D_1 \frac{\partial m}{\partial \nu} = -\gamma m \text{ on } \Gamma,$$
$$= 1, \dots, N, \ D_1 \frac{\partial m}{\partial \nu} = B_k(t) \text{ on } \partial \omega_k,$$
$$B_k(t) = B_k^0 \exp\left( -\tau \int_0^t \int_{\mathbb{R}^n - \omega_k} \tilde{\mu}_{i_0}(x, s) \eta_k(x) dx ds \right),$$
(19)

for k

with  $(\tilde{\mu}_2, \ldots, \tilde{\mu}_{i_0-1}) = F_{\varepsilon}(\tilde{m})$ . Then,  $\mu_{i_0}$  is solution to the problem

$$\frac{\partial \mu_{i_0}}{\partial t} = D_{i_0} \Delta \mu_{i_0} + m r_{i_0 - 1} \tilde{\mu}_{i_0 - 1},$$

$$D_{i_0} \frac{\partial \mu_{i_0}}{\partial \nu} = -\gamma \mu_{i_0} \text{ on } \Gamma,$$
(20)
for  $k = 1, \dots, N, \ D_{i_0} \frac{\partial \mu_{i_0}}{\partial \nu} = 0 \text{ on } \partial \omega_k.$ 

It is clear that if we prove  $F_{\varepsilon}$  and  $G_{\varepsilon}$  are well defined (the solutions of the reduced problems do exist and are in the right sets) and if  $(m, \mu_{i_0})$  is a fixed point of  $G_{\varepsilon}$ , then  $(m, \mu_2, \ldots, \mu_{i_0})$  is a solution to the problem  $(\mathcal{P}_{\varepsilon})$  (with  $(\mu_2,\ldots,\mu_{i_0-1})=F_{\varepsilon}(m)).$ 

So, we apply Schauder fixed point theorem for  $G_{\varepsilon}$ . In what follows, we denote by  $V_k = (H^1(\Omega))^k$  and  $U_k = (L^2(\Omega))^k$ . We denote by  $V'_k$  the dual space of  $V_k$ and use the classical continuous embeddings  $V_k \subset U_k \equiv U'_k \subset V'_k$ .

#### 3.2.1 Proof that $F_0$ is well defined

Let us fix  $m_0 \in (L^{\infty}(0,T : L^2(\Omega))_+$  for this section. To remain consistent with the rest, we index the components of the elements of  $V_{i_0-2}$  and  $U_{i_0-2}$ by  $\{2, \ldots, i_0 - 1\}$ . We introduce the function  $A : \begin{cases} V_{i_0-2} \times V_{i_0-2} \times U_1 \to \mathbb{R} \\ (u, v, w) \to A(u, v, w), \end{cases}$ where

$$A(u, v, w) = \sum_{i=2}^{i_0-1} \left( D_i \int_{\Omega} \nabla u_i \cdot \nabla v_i dx + \gamma \int_{\Gamma} u_i v_i d\sigma \right)$$
$$+ \sum_{i=2}^{i_0-1} \int_{\Omega} r_i u_i v_i w dx - \sum_{i=3}^{i_0-1} \int_{\Omega} r_{i-1} u_{i-1} v_i w dx$$
$$+ \sum_{i=2}^{i_0-1} \int_{\Omega} a_{i,i} u_i v_i dx - \sum_{i=2}^{i_0-2} \sum_{j=i+1}^{i_0-1} \int_{\Omega} a_{i,j} u_j v_i dx,$$

For any  $w \in U_1$ , A is bilinear on  $V_{i_0-2} \times V_{i_0-2}$ . The variational formulation of the parabolic system that defines  $F_0$  is

$$\begin{cases} \frac{d}{dt}(\mu(t), v)_{U_{i_0-2}} + A(\mu(t), v, m_0(t, \cdot)) = 0, \text{ for } v \in V_{i_0-2} \\ \mu(0) = \mu^0, \end{cases}$$
where  $\mu = \begin{pmatrix} \mu_2 \\ \vdots \\ \mu_{i_0-1} \end{pmatrix}, \mu^0 = \begin{pmatrix} \mu_2^0 \\ \vdots \\ \mu_{i_0-1}^0 \end{pmatrix}$ . This equation is to be interpreted as lows:

follows:

For all  $\varphi \in C^1([0,T])$  s.t.  $\varphi(T) = 0$ , and for all  $v \in V_{i_0-2}$ ,

$$-\int_{0}^{T} (\mu(t), v)_{U_{i_0-2}} \varphi'(t) dt - (\mu^0, v)_{U_{i_0-2}} \varphi(0) + \int_{0}^{T} A(\mu(t), v, m_0(t, \cdot)) \varphi(t) dt = 0$$

As a preliminary lemma we obtain the result below.

Lemma 1 The function A is well defined and the following estimates hold:

a) There exists a constant  $M_1 \ge 0$  such that

for all  $(u, v, w) \in V_{i_0-2} \times V_{i_0-2} \times (U_1)_+, |A(u, v, w)| \le M_1(1 + ||w||_{U_1}) ||u||_{V_{i_0-2}} ||v||_{V_{i_0-2}}$ 

b) There exist two constants  $C_1 > 0$  and  $C_2 \in \mathbb{R}$  such that

$$A(v, v, w) \ge C_1 \|v\|_{V_{i_0-2}}^2 - C_2 \|v\|_{U_{i_0-2}}^2, \quad \text{for } v \in V_{i_0-2} \text{ and } w \in (U_1)_+.$$

*Proof* a) This is clear due to the continuous embedding of  $H^1(\Omega)$  in  $L^4(\Omega)$ . b) We have

$$\sum_{i=2}^{i_0-1} \left( \int_{\Omega} D_i |\nabla v_i|^2 + \gamma \int_{\Gamma} v_i^2 d\sigma \right) \ge \left( \min_{i=2,\dots,i_0-1} D_i \right) \|\nabla v\|_{U_{i_0-2}}^2.$$
(22)

We also have

$$\left|\sum_{i=2}^{i_0-1} \int_{\Omega} a_{i,i} v_i^2 - \sum_{i=2}^{i_0-2} \sum_{j=i+1}^{i_0-1} \int_{\Omega} a_{i,j} v_j v_i\right| \le C_3 \|v\|_{U_{i_0-2}}^2 \tag{23}$$

with  $C_3$  a constant independent of  $\tilde{m}$ . It remains to estimate the terms containing w. Rearranging the sums and using the hypothesis that  $(r_i)_i$  is an increasing sequence, we have

$$\begin{split} \sum_{i=2}^{i_0-1} \int_{\Omega} r_i v_i^2 w &- \sum_{i=3}^{i_0-1} \int_{\Omega} r_{i-1} v_{i-1} v_i w = \\ &\int_{\Omega} w \Big( \frac{1}{2} \sum_{i=2}^{i_0-1} r_i v_i^2 + \frac{1}{2} \sum_{i=2}^{i_0-1} r_i v_i^2 - \sum_{i=3}^{i_0-1} r_{i-1} v_{i-1} v_i \Big), \\ &\geq \int_{\Omega} w \Big[ \frac{1}{2} r_2 v_2^2 + \frac{1}{2} r_{i_0-1} v_{i_0-1}^2 \\ &+ \sum_{i=3}^{i_0-1} \Big( \frac{1}{2} r_{i-1} v_{i-1}^2 + \frac{1}{2} r_{i-1} v_i^2 - r_{i-1} v_{i-1} v_i \Big) \Big], \\ &\geq \int_{\Omega} w \Big( \frac{1}{2} r_2 v_2^2 + \frac{1}{2} r_{i_0-1} v_{i_0-1}^2 + \frac{1}{2} \sum_{i=3}^{i_0-1} r_{i-1} (v_i - v_{i-1})^2 \Big) \geq 0. \end{split}$$

$$(24)$$

Combining the inequalities (22), (23) and (24) we get the wanted result.

Using a classical result (Lions and Magenes, 2012), we have the existence and uniqueness of a solution  $\mu \in V$  to (21) thanks to the fact that  $m_0 \in L^{\infty}(0,T:L^2(\Omega))$ . This is the reason why we regularize by convolution because  $m_0 \in X$  alone is not enough.

Then  $F_0$  is well defined. Moreover  $\mu \in C(0, T : U_{i_0-2}) \cap L^2(0, T : V_{i_0-2})$  and  $\frac{d\mu}{dt} \in L^2(0, T : (V_{i_0-2})').$ 

3.2.2 Estimates for  $F_{\varepsilon}(\tilde{m})$ 

Let us consider  $\mu = F_0(\tilde{m} * \theta_{\varepsilon})$ , with  $\tilde{m} \in X_+$  fixed. We define the application  $A_{\varepsilon} : [0,T] \times V_{i_0-2} \longrightarrow (V_{i_0-2})'$ , such that

For all  $t \in [0,T]$ ,  $u \in V_{i_0-2}$  and  $v \in V_{i_0-2}$ ,  $\langle A_{\varepsilon}(t,u), v \rangle = A(u,v,(\tilde{m} * \theta_{\varepsilon})(t,\cdot))$ 

where  $\langle \cdot, \cdot \rangle$  denotes the duality in  $((V_{i_0-2})', V_{i_0-2})$ . With this notation, we have the following equality in  $L^2(0, T : (V_{i_0-2})')$ 

$$\frac{d\mu}{dt} + A_{\varepsilon}(t,\mu(t)) = 0.$$
(25)

We then claim the following estimate for  $\mu$ :

**Proposition 1** There exists a constant  $C_4(T)$  independent of  $\tilde{m}$  and  $\varepsilon$ , such that the solution  $\mu$  of (21) satisfies

$$\|\mu\|_{L^{\infty}(0,T:U_{i_0-2})} + \|\mu\|_{L^2(0,T:V_{i_0-2})} \le C_4(T).$$

*Proof* We apply (25) to  $\mu$  which gives

$$\frac{1}{2}\frac{d}{dt}\|\mu(t)\|_{U_{i_0-2}}^2 + A\big(\mu(t),\mu(t),(\tilde{m}*\theta_{\varepsilon})(t,\cdot)\big) = 0$$

From Lemma 1 we get

$$\frac{1}{2}\frac{d}{dt}\|\mu(t)\|_{U_{i_0-2}}^2 + C_1\|\mu(t)\|_{V_{i_0-2}}^2 \le C_2\|\mu(t)\|_{U_{i_0-2}}^2.$$

The Gronwall lemma then gives us the appropriate estimate.

We now obtain the following maximum principle:

**Proposition 2** Under the hypotheses  $m^0 \ge 0$  and  $\mu_i^0 \ge 0$  for  $i = 2, ..., i_0 - 1$ , and with  $\mu = F_{\varepsilon}(\tilde{m})$  we have

$$\mu_i \ge 0 \text{ for } i = 2, \dots, i_0 - 1.$$

In other words  $F_{\varepsilon}: X_+ \to X_+^{i_0-2}$ .

Proof We denote  $\mu^- = \begin{pmatrix} \mu_2^- \\ \vdots \\ \mu_{i_0-1}^- \end{pmatrix}$ , with  $\mu_i^-(x,t) = -\min\{\mu_i(x,t), 0\}$  and

similarly  $\mu^+$ , with  $\mu_i^+(x,t) = \max\{\mu_i(x,t), 0\}$  (so that we have  $\mu = \mu^+ - \mu^-$ ). We now show that  $\mu^- = 0$ .

We apply (25) to  $\mu^-$ , noting that  $\mu^- \in L^2(0, T: V_{i_0-2})$  and that

$$\langle \frac{d\mu}{dt}, \mu^{-} \rangle = -\frac{1}{2} \frac{d}{dt} \|\mu^{-}\|_{U_{i_0-2}}^2$$

(this equality is obtained by a density argument) which gives the relation

$$\frac{1}{2}\frac{d}{dt}\|\mu^{-}\|_{U_{i_{0}-2}}^{2} = A(\mu(t), \mu^{-}(t), \tilde{m} * \theta_{\varepsilon}(t, \cdot)).$$
(26)

Now using the fact that

$$\mu_i^+\mu_i^- = 0$$
 and  $\nabla \mu_i^+ \cdot \nabla \mu_i^- = 0$ ,

we expand the expression of  ${\cal A}$ 

$$\begin{split} A(\mu,\mu^{-},\tilde{m}*\theta_{\varepsilon}(t,\cdot)) &= \\ &-\sum_{i=2}^{i_{0}-1} \int_{\Omega} D_{i} |\nabla \mu_{i}^{-}|^{2} \, dx - \sum_{i=2}^{i_{0}-1} \gamma \sum_{k=1}^{N} \int_{\partial \omega_{k}} (\mu_{i}^{-})^{2} \, d\sigma \\ &-\sum_{i=2}^{i_{0}-1} \int_{\Omega} r_{i}(\mu_{i}^{-})^{2} \tilde{m}*\theta_{\varepsilon} \, dx - \sum_{i=2}^{i_{0}-1} \int_{\Omega} a_{i,i}(\mu_{i}^{-})^{2} \, dx \\ &-\sum_{i=3}^{i_{0}-1} \int_{\Omega} r_{i-1} \mu_{i-1}^{+} \mu_{i}^{-} \tilde{m}*\theta_{\varepsilon} \, dx - \sum_{i=2}^{i_{0}-2} \sum_{j=i+1}^{i_{0}-1} \int_{\Omega} a_{i,j} \mu_{j}^{+} \mu_{i}^{-} \, dx \\ &+ \sum_{i=3}^{i_{0}-1} \int_{\Omega} r_{i-1} \mu_{i-1}^{-} \mu_{i}^{-} \tilde{m}*\theta_{\varepsilon} \, dx + \sum_{i=2}^{i_{0}-2} \sum_{j=i+1}^{i_{0}-1} \int_{\Omega} a_{i,j} \mu_{j}^{-} \mu_{i}^{-} \, dx. \end{split}$$

Proceeding as in the proof of Lemma 1, we write

$$-\sum_{i=2}^{i_0-1} \int_{\Omega} r_i(\mu_i)^2 \tilde{m} * \theta_{\varepsilon} \, dx + \sum_{i=3}^{i_0-1} \int_{\Omega} r_{i-1} \mu_{i-1}^- \mu_i^- \tilde{m} * \theta_{\varepsilon} \, dx \le 0.$$

This implies

$$\begin{split} A(\mu,\mu^{-},\tilde{m}*\theta_{\varepsilon}(t,\cdot)) &\leq \sum_{i=2}^{i_{0}-1}\sum_{j=i+1}^{i_{0}-1}\int_{\varOmega}a_{i,j}\mu_{j}^{-}\mu_{i}^{-}\,dx, \\ &\leq C\|\mu^{-}\|_{U_{i_{0}-2}}^{2}. \end{split}$$

Combining this with (26), we get

$$\frac{d}{dt} \|\mu^-\|_{U_{i_0-2}}^2 \le 2C \|\mu^-\|_{U_{i_0-2}}^2.$$

However, our hypothesis on initial conditions imposes  $\|\mu^-(t=0)\|_{U_{i_0-2}} = 0$ , so the Gronwall lemma allows to conclude  $\|\mu^-\|_{U_{i_0-2}} = 0$ , so  $\mu^- = 0$ .

#### 3.2.3 The fixed point of $G_{\varepsilon}$

For any  $(\tilde{m}, \tilde{\mu}_{i_0}) \in X^2_+$ , we consider the following problem with unknown m

$$\frac{\partial m}{\partial t} - D_i \Delta m + \Big(\sum_{j=2}^{i_0-1} r_j \mu_j + \delta\Big) m = h,$$

$$D_1 \frac{\partial m}{\partial \nu} = -\gamma m \text{ on } \Gamma,$$

$$D_1 \frac{\partial m}{\partial \nu} = \tilde{\psi}_k(t) \text{ on } \partial \omega_k, \text{ for } k = 1, \dots, N,$$
(27)

where we have defined

$$h(x,t) = \sum_{j=3}^{i_0-1} b\mu_j + 2\beta \sum_{j=2}^{i_0-1} \mu_j,$$
  
$$\tilde{\psi}_k(t) = B_k^0 \exp\left(-\tau \int_0^t \int_{\mathbb{R}^n - \omega_k} \tilde{\mu}_{i_0}(x,s)\eta_k(x) dx ds\right)$$

and finally  $(\mu_2, \ldots, \mu_{i_0-1}) = F_{\varepsilon}(\tilde{m})$ . If we define  $A_1 : \begin{cases} V_1 \times V_1 \times L^2(\Omega) \to \mathbb{R} \\ (u, v, w) \to \int_{\Omega} D_i \nabla u \cdot \nabla v \, dx + \int_{\Gamma} \gamma u v \, d\sigma + \int_{\Omega} w u v \, dx, \end{cases}$  the variational formulation of (27) is

$$\frac{d}{dt}(m,v)_{L^{2}(\Omega)} + A_{1}(m,v,\sum_{j=2}^{i_{0}-1}r_{j}\mu_{j}+\gamma) = \int_{\Omega}hv\,dx + \sum_{k=1}^{N}\tilde{\psi}_{k}(t)\int_{\partial\omega_{k}}v\,d\sigma, \text{ for } v \in V_{1}.$$
(28)

Recall that for  $j = 2, \ldots, i_0 - 1, \mu_j \in L^{\infty}(0, T : L^2(\Omega)), \mu_j \ge 0$  and  $\tilde{\mu}_{i_0} \in$  $L^2(0,T:L^2(\Omega))$ . We have the following result:

**Proposition 3** a) There exists a unique solution m of (28) with

 $\begin{array}{l} m \in L^2(0,T:V_1) \cap C(0,T:L^2(\Omega)) \ and \ \frac{\partial m}{\partial t} \in L^2(0,T:V_1'). \ We \ also \ have \\ m \geq 0, \ in \ other \ words \ m \in X_+. \\ b) \ There \ exists \ a \ constant \ C_5(T) \ independent \ of \ \varepsilon, \tilde{m}, \tilde{\mu}_{i_0} \ such \ that \end{array}$ 

$$\|m\|_{L^{\infty}(0,T:L^{2}(\Omega))} + \|m\|_{L^{2}(0,T:V_{1})} \le C_{5}(T),$$
(29)

$$\left\|\frac{\partial m}{\partial t}\right\|_{L^2(0,T:V_1')} \le C_5(T). \tag{30}$$

*Proof* a) Using the Sobolev inclusion  $H^1(\Omega) \hookrightarrow L^6(\Omega) \subset L^4(\Omega)$  we easily obtain

$$A_1(u, v, w) \le C \|u\|_{V_1} \|v\|_{V_1} \|w\|_{L^2(\Omega)}.$$

If  $w \ge 0$ , then we have

$$A_1(u, u, w) \ge \min\{D_1, \gamma\} \|u\|_{V_1}^2.$$

Finally using the fact that  $h \in L^{\infty}(0, T : L^{2}(\Omega))$ , we obtain the existence and uniqueness result in a classical manner.

Taking  $v = m^-$  as a test function and proceeding exactly as in Proposition 2, we obtain  $m \ge 0$ .

b) We note that for  $t \in [0, T]$  and  $k \in \{1, \ldots, N\}, |\tilde{\psi}_k(t)| \leq B_k^0$ . Furthermore, we deduce from Proposition 1 that there exists  $C_6(T)$ , independent of  $\tilde{m}$  and  $\tilde{\mu}_{i_0}$  such that

$$||h||_{L^2(0,T:V_1)} \le C_6(T).$$

Taking v = m in (28), we obtain

$$\frac{1}{2}\frac{d}{dt}\|m\|_{L^{2}(\Omega)}^{2} + D_{1}\int_{\Omega}\|\nabla m\|^{2}dx + \gamma\int_{\Gamma}|m|^{2}d\sigma + \int_{\Omega}\Big(\sum_{j=2}^{\iota_{0}-1}r_{j}\mu_{j} + \delta\Big)m^{2}dx$$
$$= \int_{\Omega}hm\,dx + \sum_{k=1}^{N}\tilde{\psi}_{k}(t)\int_{\partial\omega_{k}}m\,d\sigma.$$

Now we use the trace inequality

$$\left| \int_{\partial \omega_k} m d\sigma \right| \le C \|m\|_{L^1(\partial \omega_k)} \le C \|m\|_{L^2(\partial \omega_k)} \le C \|m\|_{H^1(\Omega)},$$

and we conclude with the first estimate on m. The second estimate is based on the estimate on  $A_1$ , the above inequalities on h and the trace inequality on m.

Finally, we consider problem (20) and its variational formulation

$$\frac{d}{dt}(\mu_{i_0}, v)_{L^2(\Omega)} + A_{i_0}(\mu_{i_0}, v) = \int_{\Omega} r_{i_0 - 1} m \mu_{i_0 - 1} v \, dx, \text{ for } v \in V_1, \qquad (31)$$

where

$$A_{i_0}(\mu_{i_0}, v) = D_{i_0} \int_{\Omega} \nabla \mu_{i_0} \cdot \nabla v \, dx + \gamma \int_{\Gamma} \mu_{i_0} v \, d\sigma,$$

and *m* is the solution of (27) and  $\mu_{i_0-1} = (F_{\varepsilon}(\tilde{m}))_{i_0-1}$ . We have the following result:

**Proposition 4** a) There exists a unique solution  $\mu_{i_0}$  to (31), with  $\mu_{i_0} \in L^2(0,T:V_1) \cap C(0,T:L^2(\Omega))$  and  $\frac{d\mu_{i_0}}{dt} \in L^2(0,T:V_1)$ . Furthermore,  $\mu_{i_0} \geq 0$ .

#### b) The following estimates hold

$$\|\mu_{i_0}\|_{L^{\infty}(0,T:L^2(\Omega))} + \|\mu_{i_0}\|_{L^2(0,T:V_1)} \le C_6(T),$$
$$\left\|\frac{d\mu_{i_0}}{dt}\right\|_{L^2(0,T:V_1')} \le C_6(T).$$

*Proof* a) We have for almost all  $t \in [0, T]$ 

$$\left| \int_{\Omega} r_{i_0-1} m \mu_{i_0-1} v dx \right| \leq C \|m\|_{L^2(\Omega)} \|\mu_{i_0-1}\|_{L^4(\Omega)} \|v\|_{L^4(\Omega)},$$
$$\leq C \|m\|_{L^2(\Omega)} \|\mu_{i_0-1}\|_{V_1} \|v\|_{V_1}.$$

We deduce that  $(r_{i_0-1}m\mu_{i_0-1}) \in V'_1$  and

$$\|r_{i_0-1}m\mu_{i_0-1}\|_{V_1'} \le C \|m\|_{L^2(\Omega)} \|\mu_{i_0-1}\|_{V_1},$$

which gives  $(r_{i_0-1}m\mu_{i_0-1}) \in L^2(0,T:V_1')$ . We also have

$$\|r_{i_0-1}m\mu_{i_0-1}\|_{L^2(0,T:V_1')} \le C \|m\|_{L^{\infty}(0,T:L^2(\Omega))} \|\mu_{i_0-1}\|_{L^2(0,T:V_1)}$$

In a classical manner, we get the expected existence and uniqueness results. The positivity results from  $m \ge 0, \mu_{i_0-1} \ge 0, \mu_{i_0}^0 \ge 0$ .

b) Taking  $v = \mu_{i_0}$  in (31), we obtain on one hand

$$\frac{1}{2}\frac{d}{dt}\|\mu_{i_0}\|_{L^2(\Omega)}^2 + D_{i_0}\int_{\Omega}\|\nabla\mu_{i_0}\|_{L^2(\Omega)}^2dx + \gamma\int_{\Gamma}\mu_{i_0}^2d\sigma + D_{i_0}\int_{\Omega}\mu_{i_0}^2dx = D_{i_0}\int_{\Omega}\mu_{i_0}^2dx + \int_{\Omega}r_{i_0-1}m\mu_{i_0-1}\mu_{i_0}dx.$$

On the other hand, proceeding as in the previous property we have

$$\begin{split} \left| \int_{\Omega} r_{i_0-1} m \mu_{i_0-1} \mu_{i_0} \right| &\leq C \|m\|_{L^2(\Omega)} \|\mu_{i_0-1}\|_{V_1} \|\mu_{i_0}\|_{V_1}, \\ &\leq \frac{D_{i_0}}{2} \|\mu_{i_0}\|_{V_1}^2 + \frac{C}{2D_{i_0}} \|m\|_{L^2(\Omega)}^2 \|\mu_{i_0-1}\|_{V_1}^2. \end{split}$$

Using these two previous relations and the estimates from Proposition 3 and Proposition 1, we obtain the desired result.

#### 3.3 Existence and estimates on the solution of the regularized problem

Let us define the Banach space

$$Y = \left\{ u \in L^2(0, T: V_1) : \frac{\partial u}{\partial t} \in L^2(0, T: V_1') \right\},\$$

with the norm  $||u||_Y = ||u||_{L^2(0,T:V_1)} + \left\|\frac{\partial u}{\partial t}\right\|_{L^2(0,T:V_1')}$ . Note that we have the compact embedding of Y in X from compactness embedding of  $V_1$  in  $L^2(\Omega)$  (since  $\Omega$  is bounded).

The above results prove that there exists R = R(T) independent of  $\varepsilon$  such that

$$G_{\varepsilon}(X_+^2) \subset \bar{B}_{Y^2}(0,R) \cap X_+^2, \tag{32}$$

where  $B_{Y^2}(0, R)$  is the closed ball centered on 0 of radius R in  $Y^2$ . Due to the continuous embedding of Y in X there exists  $R_1 > 0$  such that  $G_{\varepsilon}(X_+^2) \subset \Sigma$  where we denote  $\Sigma = \{u \in X_+^2 : ||u||_{X^2} \leq R_1\}$  which is a bounded closed convex subset of  $X^2$ .

We can restrict  $G_{\varepsilon}$  to  $\Sigma$  and say that  $G_{\varepsilon}$  send  $\Sigma$  to itself.

Also from (32)  $G_{\varepsilon}$  is a precompact set in  $X^2$ ; so it remains to prove the continuity of  $G_{\varepsilon}$  in order to apply Schauder fixed point theorem.

For this let us fix  $(\tilde{m}, \tilde{\mu}_{i_0}) \in X^2_+$  and choose a sequence  $(\tilde{m}_p, \tilde{\mu}_{i_0, p})_{p \in \mathbb{N}}$  in  $X^2_+$  such that

$$(\tilde{m}_p, \tilde{\mu}_{i_0, p}) \to (\tilde{m}, \tilde{\mu}_{i_0})$$
 in  $X^2_+$ 

We denote  $(\mu_{2,p}, \ldots, \mu_{i_0-1,p}) = F_{\varepsilon}(\tilde{m}_p)$  and  $(m_p, \mu_{i_0,p}) = G_{\varepsilon}(\tilde{m}_p, \tilde{\mu}_{i_0,p})$ . As above, we obtain bounds independently of p for  $|\mu_{2,p}, \ldots, \mu_{i_0-1,p}|$  and  $(m_p, \mu_{i_0,p})$ in  $L^2(0,T: H^1(\Omega)) \cap L^2(0,T: (H^1)')$ . By compactness and taking the limit  $\varepsilon$ tends to 0 we prove that

$$(m_p, \mu_{i_0, p}) \to G_{\varepsilon}(\tilde{m}, \tilde{\mu}_{i_0})$$
 in  $X^2$  strongly,

which proves the continuity of  $G_{\varepsilon}$ .

Finally by the Schauder Theorem, we obtain the existence of a solution to the problem  $(\mathcal{P}_{\varepsilon})$ . We denote this solution by  $(m_{\varepsilon}, \mu_{2,\varepsilon}, \ldots, \mu_{i_0,\varepsilon})$ . We have the existence of  $R \equiv R(T) > 0$ , independent of  $\varepsilon$ , such that

$$\|m_{\varepsilon}\|_{L^{2}(0,T:V_{1})} + \left\|\frac{\partial m_{\varepsilon}}{\partial t}\right\|_{L^{2}(0,T:(V_{1})')} \leq R, \qquad (33)$$

$$\|\mu_{i,\varepsilon}\|_{L^2(0,T:V_1)} + \left\|\frac{\partial\mu_{i,\varepsilon}}{\partial t}\right\|_{L^2(0,T:(V_1)')} \le R, \text{ for } i = 2, \cdots i_0.$$
(34)

#### 4 Stating and proof of the main result

By using the results for the regularized problem and the estimates on its solutions, we now study the original problem  $\mathcal{P}$ . Note that  $m_{\varepsilon} \in Y$ ,  $\mu_{\varepsilon} = (\mu_{2,\varepsilon}, \ldots, \mu_{i_0-1,\varepsilon}) \in Y^{i_0-2}$  and  $\mu_{i_0,\varepsilon} \in Y$ . They are a solution to the problem  $(\mathcal{P}_{\varepsilon})$  in the following variational sense

For all 
$$(v_1, v_2, \dots, v_i) \in V_i$$
  
and for  $\varphi \in C^1([0, T])$  such that  $\varphi(T) = 0$ ,

$$-\int_{0}^{T} (m_{\varepsilon}, v_{1})_{H_{0}} \varphi'(t) dt - (m^{0}, v_{1})_{H_{0}} \varphi(0)$$

$$+\int_{0}^{T} A_{1}(m_{\varepsilon}(t), v_{1}, \sum_{j=2}^{i_{0}-1} r_{j}\mu_{j,\varepsilon} + \delta)\varphi(t) dt$$

$$-\int_{0}^{T} (\mu_{\varepsilon}, v)_{H} \varphi'(t) dt - (\mu^{0}, v)_{H} \varphi(0)$$

$$+\int_{0}^{T} A(\mu_{\varepsilon}(t), v, m_{\varepsilon} * \theta_{\varepsilon}(t, \cdot))\varphi(t) dt$$

$$-\int_{0}^{T} (\mu_{i_{0},\varepsilon}, v_{i_{0}})_{H_{0}} \varphi'(t) dt - (\mu_{i_{0}}^{0}, v_{i_{0}})_{H_{0}} \varphi(0)$$

$$+\int_{0}^{T} A_{i_{0}}(\mu_{i_{0},\varepsilon(t)}, v_{i_{0}})\varphi(t) dt$$

$$=\int_{0}^{T} \int_{\Omega} \Big(\sum_{j=3}^{i_{0}-1} b\mu_{j,\varepsilon} + 2\beta \sum_{j=2}^{i_{0}-1} \mu_{j,\varepsilon}\Big) v_{1} dx \varphi(t) dt$$

$$+\int_{0}^{T} \int_{\Omega} r_{i_{0}-1} m_{\varepsilon} \mu_{i_{0}-1,\varepsilon} v_{i_{0}} dx \varphi(t) dt$$

$$+\sum_{k=1}^{N} \int_{0}^{T} \int_{\partial\omega_{k}} B_{k}^{0} \exp\left(-\tau \int_{0}^{t} \int_{\mathbb{R}-\omega_{k}} \mu_{i_{0},\varepsilon} \eta(x) dx ds\right) v_{i_{0}} d\sigma \varphi(t) dt.$$
(35)

In this section, we prove the existence of a variational solution of  $(\mathcal{P})$ , that is an element  $(m, \mu_2, \mu_3, \cdots, \mu_i) \in Y^i$  such that for any  $\varphi \in C^1([0,T])$  with  $\varphi(T) = 0$  we have

$$-\int_{0}^{T} (m, v_{1})_{L^{2}(\Omega)} \varphi'(t) dt - (m^{0}, v_{1})_{L^{2}(\Omega)} \varphi(0) +\int_{0}^{T} A_{1}(m, v_{1}, \sum_{j=2}^{i_{0}-1} r_{j}\mu_{j} + \gamma)\varphi(t) dt -\int_{0}^{T} (\mu, v)_{U_{i_{0}-2}} \varphi'(t) dt - (\mu^{0}, v)_{U_{i_{0}-2}} \varphi(0) +\int_{0}^{T} A(\mu, v, m(t, \cdot))\varphi(t) dt -\int_{0}^{T} (\mu_{i_{0}}, v_{i_{0}})_{L^{2}(\Omega)} \varphi'(t) dt - (\mu^{0}_{i_{0}}, v_{i_{0}})_{L^{2}(\Omega)} \varphi(0)$$
(36)  
$$+\int_{0}^{T} A_{i_{0}}(\mu_{i_{0}}, v_{i_{0}})\varphi(t) dt =\int_{0}^{T} \int_{\Omega} \Big(\sum_{j=3}^{i_{0}-1} b\mu_{j} + 2\beta \sum_{j=2}^{i_{0}-1} \mu_{j}\Big) v_{1} dx \varphi(t) dt +\int_{0}^{T} \int_{\Omega} r_{i_{0}-1} m\mu_{i_{0}-1} v_{i_{0}} dx \varphi(t) dt +\sum_{k=1}^{N} \int_{0}^{T} \int_{\partial\omega_{k}} B_{k}^{0} \exp\Big(-\tau \int_{0}^{t} \int_{\mathbb{R}-\omega_{k}} \mu_{i_{0}} \eta(x) dx ds\Big) v_{i_{0}} d\sigma \varphi(t) dt.$$

The main result is

**Theorem 1** There exists at least a solution  $(m, \mu_2, \dots, \mu_i) \in Y^i$  of (36).

Proof From the above section we have a solution  $(m_{\varepsilon}, \mu_{2,\varepsilon}, \cdots, \mu_{i_0,\varepsilon}) \in Y^i$  of the regularized problem  $(\mathcal{P}_{\varepsilon})$  in a variational form (35). Due to the inequalities (33),(34) and the compact embedding of Y in  $L^2(\Omega \times (0,T))$ , there exists a subsequence of  $\varepsilon$  (that we also denote  $\varepsilon$  for simplicity), as well as  $(m, \mu_2, \ldots, \mu_{i_0}) \in Y^{i_0}$  such that

$$m_{\varepsilon} \rightharpoonup m \text{ in } L^{2}(0, T : V_{1}) \text{ weakly,}$$
  

$$m_{\varepsilon} \rightarrow m \text{ in } L^{2}(0, T : L^{2}(\Omega)) \text{ strongly,}$$
(37)

and for  $i = 2, ..., i_0$ ,

$$\mu_{i,\varepsilon} \rightharpoonup \mu_i \text{ in } L^2(0,T:V_1) \text{ weakly,}$$
  

$$\mu_{i,\varepsilon} \rightarrow \mu_i \text{ in } L^2(0,T:L^2(\Omega) \text{ strongly.}$$
(38)

Let us now prove that

$$m_{\varepsilon} * \theta_{\varepsilon} \to m \text{ in } L^2(\Omega \times (0,T)) \text{ strongly.}$$
 (39)

Indeed we have

$$m_{\varepsilon} * \theta_{\varepsilon} - m = (m_{\varepsilon} - m) * \theta_{\varepsilon} + m * \theta_{\varepsilon} - m$$

We also have

$$\|(m_{\varepsilon} - m) * \theta_{\varepsilon}\|_{L^{2}} \le \|\theta_{\varepsilon}\|_{L^{1}} \|m_{\varepsilon} - m\|_{L^{2}} \le \|m_{\varepsilon} - m\|_{L^{2}}$$

so  $(m_{\varepsilon} - m) * \theta_{\varepsilon} \to 0$  in  $L^2(\Omega \times (0,T))$ . We also know that  $m * \theta_{\varepsilon} \to m$  in  $L^2$ , and we can conclude with the convergence of  $m_{\varepsilon} * \theta_{\varepsilon}$ .

Finally we use the previous convergence results to take the limit  $\varepsilon \to 0$  in (35), and obtain the expected result. Here we only deal with the most delicate term which is

$$\int_0^T \int_\Omega r_i \mu_{i,\varepsilon}(t,x) (m_\varepsilon * \theta_\varepsilon)(t,x) v_i(x) \varphi(t) dx dt.$$

Since  $v_i \in V_1$  then  $v_i \in L^6(\Omega)$  and  $v_i \varphi \in L^{\infty}(0, T : L^6(\Omega))$ . Using the fact that if  $a \in L^2$  and  $b \in L^6$  then  $ab \in L^{3/2}$ , we have

$$(m_{\varepsilon} * \theta_{\varepsilon})(t, x)v_i(x)\varphi(t) \to m(x, t)v_i(x)\varphi(t)$$
 in  $L^2(0, T : L^{3/2}(\Omega))$  strongly.

On the other hand, from the weak convergence of  $\mu_{i,\varepsilon}$  to  $\mu_i$  in  $L^2(0,T:H^1(\Omega))$ , we deduce

$$\mu_{i,\varepsilon} \rightharpoonup \mu_i$$
 in  $L^2(0,T:L^6(\Omega))$  weakly.

From those two convergence results we deduce

$$\int_0^T \int_{\Omega} r_i \mu_{i,\varepsilon}(m_{\varepsilon} * \theta_{\varepsilon}) v_i \varphi dx dt \xrightarrow[\varepsilon \to 0]{} \int_0^T \int_{\Omega} r_i \mu_i m v_i \varphi dx dt.$$

This achieves the proof of the theorem.

#### **5** Conclusion

We have introduced a model combining chemical prion-like replication of oligomers and spatial diffusion, as well as neurotoxicity. Those processes are essential for the early stage development of Alzheimer's disease, and it is of great interest to understand their relative impact on the later stages of the disease. To the best of our knowledge, this work is the first use of reactiondiffusion equations to describe the secondary nucleation process leading to the formation of  $A\beta$  oligomers on the one hand, and the pathological effects of  $A\beta$  oligomers on the neuronal activity on the other hand. The results proved here establish a strong mathematical framework for this model, and allow us to go further with the use of this model in a quantitative context. The mathematical proofs are obtained using classical methods, but they were adapted in order to deal with the specificities of our model. In particular in our model the formation of oligomers directly impacts the production of monomers by neurons, and the system had to be split into two parts in order to get existence results. Future work will be dedicated to the practical use of the model to interpret the relative importance of the different parameters. The goal is to include this local model in a multi-scale model so as to be able to carry out a quantitative comparison with data. Another important development aspect will be to validate and improve the model if need be, in collaboration with biologists.

#### Conflict of interest

The authors declare that they have no conflict of interest.

#### References

- Andrade-Restrepo M, Lemarre P, Pujo-Menjouet L, Tine LM, Ciuperca SI (2020) Modeling the spatial propagation of  $A\beta$  oligomers in Alzheimer's Disease. In: ESAIM: ProcS, Numerical and mathematical modeling for biological and medical applications: deterministic, probabilistic and statistic description, EDP Sciences, vol 67, pp 30–45, DOI 10.1051/proc/202067003
- Bertsch M, Franchi B, Marcello N, Tesi MC, Tosin A (2016) Alzheimer's disease: a mathematical model for onset and progression. Mathematical medicine and biology: a journal of the IMA 34(2):193–214
- Bertsch M, Franchi B, Tesi MC, Tosin A (2017) Microscopic and macroscopic models for the onset and progression of Alzheimer's disease. Journal of Physics A: Mathematical and Theoretical 50(41):414003
- Carbonell F, Iturria-Medina Y, Evans AC (2018) Mathematical modeling of protein misfolding mechanisms in neurological diseases: a historical overview. Frontiers in Neurology 9:37
- Ciuperca IS, Dumont M, Lakmeche A, Mazzocco P, Pujo-Menjouet L, Rezaei H, Tine LM (2018) Alzheimer's disease and prion: analysis of an in vitro mathematical model. Discrete and Continuous Dynamical Systems-Series B
- Čižas P, Jekabsone A, Borutaite V, Morkūniene R (2011) Prevention of amyloid-beta oligomer-induced neuronal death by EGTA, estradiol, and endocytosis inhibitor. Medicina 47(2):15
- Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, Otzen DE, Vendruscolo M, Dobson CM, Knowles TP (2013) Proliferation of Amyloid- $\beta$ 42 aggregates occurs through a secondary nucleation mechanism. Proceedings of the National Academy of Sciences 110(24):9758–9763
- Doumic M, Goudon T, Lepoutre T (2009) Scaling limit of a discrete prion dynamics model. Commun Math Sci 7(4):839–865
- Eigen M (1996) Prionics or the kinetic basis of prion diseases. Biophysical chemistry  $63(1){:}\mathrm{A1}{-}\mathrm{A18}$
- Eleuteri S, Di Giovanni S, Rockenstein E, Mante M, Adame A, Trejo M, Wrasidlo W, Wu F, Fraering PC, Masliah E, et al. (2015) Blocking  $A\beta$  seeding-mediated aggregation and toxicity in an animal model of

Alzheimer's Disease: A novel therapeutic strategy for neurodegeneration. Neurobiology of disease 74:144

- Elliott C, Rojo AI, Ribe E, Broadstock M, Xia W, Morin P, Semenov M, Baillie G, Cuadrado A, Al-Shawi R, et al. (2018) A role for APP in Wnt signalling links synapse loss with  $\beta$ -amyloid production. Translational psychiatry 8(1):179
- Greer ML, Pujo-Menjouet L, Webb GF (2006) A mathematical analysis of the dynamics of prion proliferation. Journal of theoretical biology 242(3):598– 606
- Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid  $\beta$ -peptide. Nature reviews Molecular cell biology 8(2):101
- Hardy J (2003) The relationship between amyloid and tau. Journal of Molecular Neuroscience 20(2):203–206
- Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054):184–186
- Harper JD, Lansbury Jr PT (1997) Models of amyloid seeding in alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annual review of biochemistry 66(1):385–407
- Helal M, Hingant E, Pujo-Menjouet L, Webb GF (2014) Alzheimer's disease: analysis of a mathematical model incorporating the role of prions. Journal of mathematical biology 69(5):1207–1235
- Helal M, Igel-Egalon A, Lakmeche A, Mazzocco P, Perrillat-Mercerot A, Pujo-Menjouet L, Rezaei H, Tine LM (2018) Stability analysis of a steady state of a model describing Alzheimer's disease and interactions with prion proteins. Journal of mathematical biology pp 1–25
- Hiltunen M, van Groen T, Jolkkonen J (2009) Functional roles of amyloid- $\beta$  protein precursor and amyloid- $\beta$  peptides: evidence from experimental studies. Journal of Alzheimer's Disease 18(2):401–412
- Ittner LM, Götz J (2011) Amyloid- $\beta$  and tau—a toxic pas de deux in Alzheimer's disease. Nature Reviews Neuroscience 12(2):67
- Jack Jr CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, et al. (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology 12(2):207–216
- Lions JL, Magenes E (2012) Non-homogeneous boundary value problems and applications, vol 1. Springer Science & Business Media
- Matthaeus F (2009) The spread of prion diseases in the brain models of reaction and transport networks. Journal of Biological Systems 17(04):623–641
- Matthäus F (2006) Diffusion versus network models as descriptions for the spread of prion diseases in the brain. Journal of theoretical biology 240(1):104-113
- Morales R, Duran-Aniotz C, Castilla J, Estrada L, Soto C (2012) De novo induction of amyloid- $\beta$  deposition in vivo. Molecular psychiatry 17(12):1347

- Nowak MA, Krakauer DC, Klug A, May RM (1998) Prion infection dynamics. Integrative Biology: Issues, News, and Reviews: Published in Association with The Society for Integrative and Comparative Biology 1(1):3–15
- Oda T, Pasinetti G, Osterburg H, Anderson C, Johnson S, Finch C (1994) Purification and Characterization of Brain Clusterin. Biochemical and Biophysical Research Communications 204(3):1131 – 1136, DOI https://doi.org/10.1006/bbrc.1994.2580, URL http://www.sciencedirect.com/science/article/pii/S0006291X84725800
- Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine W, Snyder SW, Holzman TF, Krafft GA, Finch CE (1995) Clusterin (apoJ) Alters the Aggregation of Amyloid  $\beta$ -Peptide (A $\beta$ 1-42) and Forms Slowly Sedimenting A $\beta$ Complexes That Cause Oxidative Stress. Experimental Neurology 136(1):22 – 31, DOI https://doi.org/10.1006/exnr.1995.1080, URL http://www.sciencedirect.com/science/article/pii/S0014488685710801
- Ohm T, Müller H, Braak H, Bohl J (1995) Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience 64(1):209–217
- Olsson TT, Klementieva O, Gouras GK (2018) Prion-like seeding and nucleation of intracellular amyloid- $\beta$ . Neurobiology of disease 113:1–10
- Perrin RJ, Fagan AM, Holtzman DM (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461(7266):916
- Raj A, Kuceyeski A, Weiner M (2012) A network diffusion model of disease progression in dementia. Neuron 73(6):1204–1215
- Rasmussen J, Jucker M, Walker LC (2017) A $\beta$  seeds and prions: how close the fit? Prion 11(4):215–225
- Sengupta U, Nilson AN, Kayed R (2016) The role of amyloid- $\beta$  oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 6:42–49
- Smith AD (2002) Imaging the progression of Alzheimer pathology through the brain. Proceedings of the National Academy of Sciences 99(7):4135–4137
- Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Reviews Neuroscience 4(1):49
- Sowade RF, Jahn TR (2017) Seed-induced acceleration of amyloid- $\beta$  mediated neurotoxicity in vivo. Nature communications 8(1):512
- Storandt M, Grant EA, Miller JP, Morris JC (2002) Rates of progression in mild cognitive impairment and early Alzheimer?s disease. Neurology 59(7):1034–1041
- Stumpf MP, Krakauer DC (2000) Mapping the parameters of prioninduced neuropathology. Proceedings of the National Academy of Sciences 97(19):10573–10577
- Vasseur A, Poupaud F, Collet JF, Goudon T (2002) The Beker–Döring System and Its Lifshitz–Slyozov Limit. SIAM Journal on Applied Mathematics 62(5):1488–1500
- Velázquez J (1998) The Becker–Döring equations and the Lifshitz–Slyozov theory of coarsening. Journal of statistical physics 92(1-2):195–236

- Xiao T, Zhang W, Jiao B, Pan CZ, Liu X, Shen L (2017) The role of exosomes in the pathogenesis of Alzheimer's disease. Translational neurodegeneration 6(1):3
- Yankner BA (1996) Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron<br/>  $16(5){:}921-932$
- Zhao LN, Long HW, Mu Y, Chew LY (2012) The toxicity of amyloid  $\beta$  oligomers. International journal of molecular sciences 13(6):7303–7327